Pages that link to "Q24302466"

The following pages link to Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function (Q24302466):

Displaying 40 items.

• Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta (Q7117825) ‎ (← links)
• Anti-Inflammatory and Organ-Protective Effects of Resveratrol in Trauma-Hemorrhagic Injury (Q26798377) ‎ (← links)
• Autoimmunity in primary T-cell immunodeficiencies. (Q30251616) ‎ (← links)
• The Concise Guide to PHARMACOLOGY 2013/14: enzymes. (Q30486745) ‎ (← links)
• β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. (Q33578997) ‎ (← links)
• Proteomic identification of altered cerebral proteins in the complex regional pain syndrome animal model. (Q34275621) ‎ (← links)
• Non-canonical regulation of phosphatidylinositol 3-kinase gamma isoform activity in retinal rod photoreceptor cells (Q35078762) ‎ (← links)
• The p110δ subunit of PI3K regulates bone marrow-derived eosinophil trafficking and airway eosinophilia in allergen-challenged mice (Q36045558) ‎ (← links)
• PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma (Q36086507) ‎ (← links)
• The Genome-Wide Expression Profile of Saussurea lappa Extract on House Dust Mite-Induced Atopic Dermatitis in Nc/Nga Mice (Q36107242) ‎ (← links)
• The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases (Q36286414) ‎ (← links)
• Inhibition of phosphoinositide 3-kinase delta attenuates experimental autoimmune encephalomyelitis in mice (Q36492808) ‎ (← links)
• Phosphatidylinositol-3,4,5-triphosphate and cellular signaling: implications for obesity and diabetes. (Q36702291) ‎ (← links)
• Selective PI3Kδ inhibitors, a review of the patent literature (Q37948112) ‎ (← links)
• Inflammation and lipid signaling in the etiology of insulin resistance (Q38007632) ‎ (← links)
• B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies. (Q38124120) ‎ (← links)
• Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthma (Q38175444) ‎ (← links)
• Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings (Q38261144) ‎ (← links)
• Drugging PI3K in cancer: refining targets and therapeutic strategies (Q38539217) ‎ (← links)
• Emerging pharmaceutical therapies for COPD. (Q38645203) ‎ (← links)
• Advanced Role of Neutrophils in Common Respiratory Diseases (Q38739370) ‎ (← links)
• Akt Signaling Pathway in Macrophage Activation and M1/M2 Polarization. (Q39099628) ‎ (← links)
• Phosphoinositide 3-Kinase Is Involved in Mediating the Anti-inflammation Effects of Vasopressin (Q39109218) ‎ (← links)
• An investigation of the anti-inflammatory effects and a potential biomarker of PI3Kδ inhibition in COPD T cells. (Q40211028) ‎ (← links)
• First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases (Q41991078) ‎ (← links)
• Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies (Q42320922) ‎ (← links)
• Arginase activity in alternatively activated macrophages protects PI3Kp110δ deficient mice from dextran sodium sulfate induced intestinal inflammation (Q44086481) ‎ (← links)
• Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729. (Q44490096) ‎ (← links)
• Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases (Q46430396) ‎ (← links)
• Drosophila muscles regulate the immune response against wasp infection via carbohydrate metabolism (Q46463705) ‎ (← links)
• Inhibition of PI4K IIIα radiosensitizes in human tumor xenograft and immune-competent syngeneic murine tumor model. (Q47153501) ‎ (← links)
• Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies (Q47388561) ‎ (← links)
• Activity of the PI3K-δ,γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma (Q49887083) ‎ (← links)
• Bacille Calmette–Guerin Complications in Newly Described Primary Immunodeficiency Diseases: 2010–2017. (Q55514852) ‎ (← links)
• Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study (Q58697794) ‎ (← links)
• Targeting PI3K in cancer: mechanisms and advances in clinical trials (Q64254413) ‎ (← links)
• The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies. (Q64880506) ‎ (← links)
• Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome. (Q64883379) ‎ (← links)
• Inhibition of PI3Kδ improves systemic lupus in mice (Q87134330) ‎ (← links)
• Progress in the mechanism and targeted drug therapy for COPD (Q101038363) ‎ (← links)